InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
3
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Vieser Jaime, Director. Officer active across 3 companies, notably Ziopharm Oncology INC. Cumulatively, 12 reports have been recorded. Split: 3 buys · 1 sell. Total volume traded: €954k. Activity tracked since 4 March 2021. The latest transaction was filed on 23 July 2026 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Vieser Jaime
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations12 total
8,789 shares@ US$1.92Common StockSEC:0001193125-26-318100:0
6,515 shares@ US$2.590.33% mcap1.8% of flowCommon StockSEC:0001193125-26-201557:0
5,839 shares@ US$2.891.7% of flowCommon StockSEC:0001193125-26-014115:0
5,340 shares@ US$3.161.8% of flowCommon StockSEC:0001193125-25-301033:0
3,400 shares0Common StockSEC:0000950170-25-094386:0
17,465 shares0Common StockSEC:0000950170-25-054429:0
2,182 shares@ US$2.010.5% of flowCommon StockSEC:0000950170-25-001257:0
25,000 sharesClass A Ordinary Share, par value $0.0001 per shareSEC:0001213900-24-109470:0
Canonical exit: 16 Mar 2025 (T+90)
1,250,000 shares@ US$0.6599.5% of flowCommon StockSEC:0000899243-22-037274:0
Canonical exit: 27 Feb 2023 (T+90)
40,000 shares0Common StockSEC:0000899243-22-023985:0
100,000 shares@ US$1.91100.0% of flowCommon StockSEC:0001209191-21-059131:0
Canonical exit: 28 Dec 2021 (T+90)
4,167 shares0Common StockSEC:0001209191-21-030745:0
12 of 12 declarations
About Vieser Jaime
Jaime Vieser is a director at ZIOPHARM ONCOLOGY INC and Alaunos Therapeutics, Inc. In this role, he is involved in the strategic and operational management of the companies. With expertise in the pharmaceutical sector, he contributes to innovation and service improvement.
